In people suffering from seasonal allergic rhinitis with predominant symptoms of rhinorrhea, the use of Bencycloquidium bromide nasal spray is both safe and highly effective.

A multi-center observational study aimed to assess the safety and effectiveness of using a nasal spray containing the M receptor antagonist Bencycloquidium bromide for treating seasonal allergic rhinitis, where the predominant symptom is runny nose.

In total, 134 individuals diagnosed with seasonal allergic rhinitis participated in the study, comprising 71 males and 63 females, with a median age of 38 years. The study assessed the total nasal symptom score (TNSS) and the visual analogue scale (VAS) for total nasal symptoms over a 2-week period of treatment using the Bencycloquidium bromide nasal spray.

From day 0 to day 14, there was a noticeable decrease in both the TNSS and the VAS scores related to nasal symptoms and rhinorrhea. Moreover, the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score showed a significant reduction during this period (Table 1).

The occurrence of adverse reactions was infrequent, and there were no instances of serious adverse events throughout the entire study.

Intranasal Bencycloquidium bromide demonstrates notable effectiveness and a favorable safety profile in relieving seasonal allergic rhinitis.